Table 1 Drug synergy scores via three different methods

CI by Loewe additivity

5.33

1.14

1.20

1.06

2.15

1.18

1.49

9.39

0.95^c

0.84^a

0.96^c

DEF

mTOR

1.66

1.34

1.03

1.47

2.22

3.15

9.25

2.43

0.51^a

0.57^a

INK

0.85^c

1.45

2.12

1.16

1.71

1.53

0.98

1.32

1.03

PAC

MT

2.18

2.41

1.67

3.52

1.71

0.66

1.25

1.08

VIN

1.59

1.85

3.06

2.91

3.09

1.96

2.13

AAG

HSP

4.59

3.34

1.50

2.64

2.92

2.45

AUY

1.69

3.72

5.86

2.10

1.16

PS

PROT

4.92

6.48

1.81

1.16

MG

4.40

1.99

3.44

ETO

DNA

4.02

6.48

GEM

1.70

PAN

HDAC

Sum of EOB by Bliss independence

-0.01

-0.24

-0.24

0.17^b

-0.39

-0.12

-0.17

-0.05

-0.42

0.20^a

-0.04

DEF

mTOR

-0.12

-0.54

0.41^b

-0.05

-0.31

-0.20

-0.66

-0.49

0.67^a

0.41^a

INK

-0.87

-0.37

-0.65

-0.25

-0.26

-1.09

-0.98

-0.17

-0.15

PAC

MT

-0.48

-0.64

-0.41

-0.57

-1.34

-1.18

-0.11

-0.16

VIN

-0.75

-0.69

-0.86

-0.51

-0.58

-0.59

-0.30

AAG

HSP

-1.26

-1.06

-0.46

-0.91

-0.95

-0.43

AUY

-0.81

-0.81

-0.90

-0.43

0.11^b

PS

PROT

-0.68

-0.75

-0.54

-0.05

MG

-1.14

-0.49

-0.15

ETO

DNA

-0.57

-0.30

GEM

-0.47

PAN

HDAC

ΔDSS by area under curve (%)

-9.82

-0.58

-1.61

5.76^b

-5.83

0.86

-0.76

-0.57

1.61^c

7.07^a

3.01^c

DEF

mTOR

3.95

0.87

14.80^b

5.91

-2.99

-2.50

-4.96

4.85

21.09^a

14.08^a

INK

2.08^c

2.45

-6.09

5.71

5.98

-5.47

-4.52

4.68

2.77

PAC

MT

2.90

-3.76

4.94

1.72

-2.53

-5.76

10.18

4.64

VIN

2.41

0.43

-0.31

7.28

5.92

4.44

1.88

AAG

HSP

-7.06

-1.59

11.43

0.79

2.58

2.61

AUY

-3.68

-1.82

0.54

5.03

9.11^b

PS

PROT

2.13

-0.90

3.92

5.67

MG

-3.66

8.33

2.89

ETO

DNA

3.04

-1.14

GEM

-0.93

PAN

HDAC